Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Roche Holding AG's Average Total Inventories for the quarter that ended in Jun. 2026 was CHF7,787 Mil. Roche Holding AG's Revenue for the
six
months ended in Jun. 2026 was CHF31,452 Mil.
Roche Holding AG's Inventory-to-Revenue for the quarter that ended in Jun. 2026 was 0.25.
Roche Holding AG's Inventory-to-Revenue for the quarter that ended in Jun. 2026
increased
from Dec. 2025 (0.24) to Dec. 2025 (0.25)
An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:
1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Roche Holding AG's Days Inventory for the
six
months ended in Jun. 2026 was 178.05.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Roche Holding AG's Inventory Turnover for the quarter that ended in Jun. 2026 was 1.02.
Roche Holding AG (XSWX:RO) Inventory-to-Revenue Explanation
An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:
1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.
Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:
1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.
More Related Terms:
1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Roche Holding AG's Days Inventory for the
six
months ended in Jun. 2026 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Roche Holding AG Inventory-to-Revenue Related Terms
Roche Holding AG Inventory-to-Revenue Historical Data
* Premium members only.
The historical data trend for Roche Holding AG's Inventory-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:RO vs LLY, JNJ, ABBV: Inventory-to-Revenue Comparison
For the Drug Manufacturers - General subindustry, Roche Holding AG's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Roche Holding AG Inventory-to-Revenue vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Roche Holding AG's Inventory-to-Revenue distribution charts can be found below:
* The bar in red indicates where Roche Holding AG's Inventory-to-Revenue falls into.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Roche Holding AG's Inventory-to-Revenue for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Roche Holding AG (XSWX:RO) has a Inventory-to-Revenue of 0.25 as of Jun. 2026. Inventory-to-Sales ratio is the total inventories divided by total sales. View historical data on Roche Holding AG and its competitors.
Is Roche Holding AG's Inventory-to-Revenue too high?
Roche Holding AG's current Inventory-to-Revenue is 0.25. Overall, Roche Holding AG has a GF Score™ of 74/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Roche Holding AG's Inventory-to-Revenue compare to LLY and JNJ?
Roche Holding AG's Inventory-to-Revenue of 0.25 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventory-to-Revenue for a Drug Manufacturers company?
A good Inventory-to-Revenue depends on the Drug Manufacturers industry context. However, Inventory-to-Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventory-to-Revenue mean?
A high Inventory-to-Revenue can signal that a stock is expensive relative to its fundamentals. Inventory-to-Sales ratio is the total inventories divided by total sales. View historical data on Roche Holding AG and its competitors. Roche Holding AG's current Inventory-to-Revenue is 0.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Roche Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Roche Holding AG (XSWX:RO) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF271.08, compared to a current price of CHF361.80 — trading 33.5% above its estimated fair value. The current Inventory-to-Revenue is 0.25. Roche Holding AG's overall GF Score™ is 74/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventory-to-Revenue calculated?
Inventory-to-Revenue is calculated from a company's financial statements. For Roche Holding AG (XSWX:RO), the current Inventory-to-Revenue is 0.25 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Roche Holding AG (XSWX:RO) Overvalued in 2026?
Based on GuruFocus' analysis, Roche Holding AG stock appears to be overvalued.
The current stock price of CHF361.80 is trading 33.5% above its estimated GF Value™ of CHF271.08.
GuruFocus considers Roche Holding AG to be Significantly Overvalued.
Key valuation signals for XSWX:RO:
Inventory-to-Revenue: 0.25
GF Value™: CHF271.08 vs. price of CHF361.80 (33.5% above fair value)
No single metric tells the full story. See the XSWX:RO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 40% of pharmaceutical sales, and centralized and point-of-care diagnostics for two-thirds of diagnostic-related sales.
74GF Score
Get the complete analysis for XSWX:RO
Inventory-to-Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:RO has been successfully added to your 
